Antiviral Activity of Luteolin against Pseudorabies Virus In Vitro and In Vivo.
Xiaoyu MenSu LiXiaojing CaiLian FuYi ShaoYan ZhuPublished in: Animals : an open access journal from MDPI (2023)
Pseudorabies virus (PRV) can cause acute swine disease leading to economic losses worldwide and is a potential causative agent of viral encephalitis in humans. Although effective vaccines are available, an increasing number of variants have emerged in China, and identifying effective antiviral agents against PRV to prevent latent infection is essential. In this study, we assessed the antiviral activity of luteolin against PRV in vitro and in vivo. Luteolin was found to significantly inhibit PRV at a noncytotoxic concentration (70 μM), with an IC 50 of 26.24 μM and a selectivity index of 5.64. Luteolin inhibited the virus at the replication stage and decreased the expression of viral mRNA and gB protein. Luteolin reduced the apoptosis of PRV-infected cells, improved the survival rate of mice after lethal challenge, reduced the viral loads in the liver, kidney, heart, lung, and brain, reduced brain lesions, and slowed inflammation and oxidation reactions. Our results showed that luteolin has promise as a new alternative antiviral drug for PRV infection.
Keyphrases
- sars cov
- cell cycle arrest
- induced apoptosis
- binding protein
- endoplasmic reticulum stress
- white matter
- poor prognosis
- liver failure
- resting state
- type diabetes
- cell death
- risk assessment
- metabolic syndrome
- big data
- small molecule
- adipose tissue
- copy number
- disease virus
- brain injury
- amino acid
- hepatitis b virus
- hydrogen peroxide
- aortic dissection
- artificial intelligence
- functional connectivity
- electronic health record
- adverse drug